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ABSTRACT
Osteosarcoma (OS) is a highly aggressive bone tumor that usually arises intramedullary at the
extremities of long bones. Due to the fact that the peak of incidence is in the growth spurt of
adolescence, the speciﬁc anatomical location, and the heterogeneity of cells, it is believed that
osteosarcomagenesis is a process associated with bone development. Different studies in murine
models showed that the tumor-initiating cell in OS could be an uncommitted mesenchymal stem
cell (MSC) developing in a speciﬁc bone microenvironment. However, only a few studies have
reported transgene-induced human MSCs transformation and mostly obtained undifferentiated
sarcomas. In our study, we demonstrate that activator protein 1 family members induce osteo-
sarcomagenesis in immortalized hMSC. c-JUN or c-JUN/c-FOS overexpression act as tumorigenic
factors generating OS with ﬁbroblastic or pleomorphic osteoblastic phenotypes, respectively.
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SIGNIFICANCE STATEMENT
During the last decades survival rate for patients with nonmetastatic osteosarcoma (OS) has
increased notably, but metastatic and refractory OS maintain a low survival rate. The develop-
ment of more effective OS treatments requires a deep knowledge about the origin and develop-
ment of this tumor.
INTRODUCTION
Osteosarcoma (OS) is a highly malignant tumor
represented in children and young adults, which
is the most frequent primary bone tumors of non-
hematopoietic origin [1]. OS mostly arises intra-
medullary in the epiphysis of the growing bone
like femur, tibia, and humerus [2]. Histologically,
OS is a malignant mesenchymal tumor formed by
spindle-shaped cells producing aberrant immature
bone matrix, also called osteoid [3]. OS is a het-
erogeneous tumor and its classic conventional
form can be further subdivided into osteoblastic,
chondroblastic, or ﬁbroblastic, among other sub-
types, depending on the main matrix produced by
the tumor [3]. With multi-agent chemotherapy
and surgical resection, the 5-year survival rate for
OS patients is still 65%–70% [2].
OS pathogenesis is a complex process which is
not completely understood. Patients with heredi-
tary syndromes like retinoblastoma (RB) and Li-
Fraumeni are predisposed to OS development;
RB1 and TP53 are also frequently mutated in
sporadic cases of OS [4]. Those genes regulate
processes like DNA replication, cell cycle arrest,
apoptosis, senescence, and DNA damage
response. There is increasing evidence that OS
most likely derives from mesenchymal stem cell
(MSC) or MSC-derived cell types, although the
exact cell of origin is unclear [2]. Murine models
show that it is possible to induce OS formation
if deleting some of the previously mentioned
genes along the osteogenic differentiation line-
age [5, 6] or if cells are implanted in the proper
osteoinductive microenvironment [7]. Further-
more, mouse MSCs were also used to generate
other sarcomas models by the introduction of
FUS/DDTI3, EWSR1/FLI1, PAX/FOXO1, and SYT-
SSX-1 fusion genes generating myxoid liposar-
coma, Ewing’s sarcoma, rhabdomyosarcoma,
and synovial sarcoma [8]. These studies under-
lined the importance of the microenvironment
and the type of genetic hits in sarcoma pheno-
type originated by mouse MSCs transformation.
In contrast, human MSCs (hMSC) transfor-
mation is a more complex process. Human
aCellular Biotechnology Unit,
Instituto de Salud Carlos III,
Madrid, Spain; bHaematopoietic
Stem Cell Laboratory, The
Francis Crick Institute, London,
UK; cMolecular Image Core
Unit, Spanish National Cancer
Research Centre, Madrid,
Spain; dHospital Universitario
Central de Asturias—Instituto
de Investigación Sanitaria del
Principado de Asturias and,
Instituto Universitario de
Oncología del Principado de
Asturias, Oviedo, Spain;
eCIBER de Cáncer (CIBERONC),
Madrid, Spain; fPathology
Department, University of
Valencia, Valencia, Spain
Correspondence: Javier García-
Castro, Ph.D., Unidad de
Biotecnología Celular, Instituto de
Salud Carlos III, Lab. 51-00-036,
Ctra Majadahonda-Pozuelo, Km
2, E-28220, Majadahonda,
Madrid, Spain. Telephone:
34-918-223-288; e-mail:
jgcastro@isciii.es
†Contributed equally.
Received January 11, 2018;
accepted for publication May 28,
2018.; ﬁrst published online in
STEM CELLS EXPRESS July 12, 2018.
http://dx.doi.org/
10.1002/stem.2869
This is an open access article
under the terms of the Creative
Commons Attribution-
NonCommercial License, which
permits use, distribution and
reproduction in any medium,
provided the original work is
properly cited and is not used for
commercial purposes.
STEM CELLS 2018;36:1487–1500 www.StemCells.com ©2018 The Authors Stem Cells published by Wiley
Periodicals, Inc. on behalf of AlphaMed Press
CANCER STEM CELLS
spindle cell sarcomas [9, 10], tumors with smooth muscle and
bone-forming cells [11], and undifferentiated sarcomas [12]
were induced introducing hTERT overexpression, p53 and RB
pathways inhibition, and oncogenic RAS mutations in hMSC.
One study demonstrated that hMSC transformation can be
induced by RB knockdown and c-MYC overexpression, generat-
ing bone-like tumors [13]. In addition, enforced expression of
fusion oncogenes in wild-type hMSCs was not sufﬁcient to
induce sarcomagenesis [8, 14]. However, the expression of
FUS/DDTI3 was able to re-direct the sarcomagenic program of
previously transformed hMSCs and induced the formation of
myxoid liposarcomas in vivo [15]. Interestingly, in all the stud-
ies, several genetic hits were required to transform hMSCs and
conﬁrmed the idea that speciﬁc mutations can force tumor
phenotype.
The activator protein 1 (AP-1) complex is a transcriptional
regulator that can be formed by Jun, Fos, and members of the
activating transcription factor (ATF) family which binds as
homo- and/or heterodimers and regulates promoter regions of
various genes [16]. AP-1 complex regulates proliferation, differ-
entiation, and bone metabolism. Various members of the AP-1
complex are expressed differentially during osteoblast differenti-
ation [17], where c-Fos knockout alters endochondral differenti-
ation [18] and c-Jun is essential for embryonic development
[17]. Both c-Fos and c-Jun upregulations are seen in high-grade
OS suggesting their involvement in osteosarcomagenesis [19].
Similarly to AP-1, nuclear factor-kB (NF-kB) is a dimeric tran-
scription factor complex implicated in the regulation of cell pro-
liferation, survival, neoplastic transformation, and immune and
inﬂammatory response. Despite AP-1 and NF-kB binds to dis-
tinct enhancer motif, it was described synergism and cross-
coupling between the different members of these transcription
factors families in cancer [20, 21].
In this article, we demonstrate that the overexpression of c-
JUN and c-JUN/c-FOS in immortalized hMSC is sufﬁcient to
induce cell transformation and OS formation. Moreover, depend-
ing on the AP-1 members overexpressed, tumors develop differ-
ent OS phenotypes. Thus, c-JUN overexpression generates
ﬁbroblastic OS and the double expression of c-JUN/c-FOS induces
pleomorphic osteoblastic phenotype.
MATERIALS AND METHODS
Cell Culture
Immortalized hMSCs deﬁned as 3 HITs or just 3H cells in the
text were kindly provided by Dr. Funes. Those cells are hMSC
overexpressing hTERT and HPV-16 E6/E7, which extend cell life-
span in culture and abrogate p53 and pRB function, respectively
[9], although they are not tumorigenic when inoculated in
immunodeﬁcient mice. Normal hMSCs were isolated from
healthy donors after signing an informed consent. All cell lines
were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum, 1% penicillin/strep-
tomycin, and 2 mM L-glutamine (Lonza, Basel, Switzerland) and
routinely tested for mycoplasma infection.
c-DNAs of c-FOS and c-JUN were cloned into pOTB7 and
pWPI plasmids to generate lentiviral vectors able to induce the
constitutive expression of c-FOS and c-JUN; each vector carries
TdTomato and enhanced green ﬂuorescent protein (EGFP) as
reporter ﬂuorescent markers, respectively. Two additional pOTB7
and pWPI plasmids carrying only TdTomato or EGFP ﬂuorescent
markers were used to generate empty control vectors. Lentiviral
particles were produced in HEK-293 cells by transient calcium
phosphate transfection. Supernatants were collected 48 hours
after transfection, ultracentrifugated, and the concentrated lenti-
viral particles were stored at −80C. Then, cells were transduced
with these lentiviral vectors generating 3 HIT cells overexpressing
c-JUN (3H-JUN) or c-JUN and c-FOS (3H-JUN/FOS) genes; 3 HITs
cells were also transduced with empty vectors to generate a con-
trol cell line (3H-). Four days after transduction, cells were
ﬂuorescence-activated cell sorted and shortly ampliﬁed in vitro to
generate a cell stock which was used in the following
experiments.
In Vitro Growth Assays
For proliferation assay, 2 × 105 cells were seeded in 75 cm2 ﬂasks.
Cells were trypsinized, counted, and replated in the same condi-
tions every day during 48 hours. Alternatively, 2.5 × 103 cells were
seeded onto each well of E-Plate L8 plates within an iCELLigence
system (ACEA Biosciences, San Diego, CA) and left to proliferate in
growth media at 37C with 5% CO2 for 10 days. In the iCELLigence
system, cells adhere to micro-electrodes which continuously mea-
sure alterations in electrical impedance, thus allowing the real-
time monitoring of cell proliferation. Cell status is expressed as
normalized cell index (Cell index relative to that of the time the
cells need to attach to the plates, 9 hours). Data were analyzed in
the real-time cell analysis (RTCA) data analysis software 1.0 (ACEA
Biosciences). In cell cycle experiments, 60% conﬂuence cells were
ﬁxed using 70% ice-cold ethanol, permeabilized with a solution of
phosphate-buffered saline (PBS) with Triton 0.1%, and stained with
40,6-diamidino-2-phenylindole (DAPI) (10 μg/mL) (ThermoFisher,
Waltham, MA) for DNA labeling. All cells were analyzed in a BD
LSRFortesa ﬂow cytometer (BD Bioscience, Madrid, Spain). Cell
cycle statistics were obtained with FlowJo7.6 (FlowJo, Ashland,
OR). For multilayer growth study, cells were seeded subconﬂuent
and allowed to reach complete conﬂuency. Cells were stained
using Texas Red-X phalloidin and DAPI according to manufacturer
protocol (ThermoFisher). A confocal multispectral microscope
Leica TCS-SP5 (Leica Microsystems,Wetzlar, Germany) was used in
this experiment. Stacks of 20 layers were acquired and orthogonal
sections were processed using Leica LAS AF (Leica Microsystems).
Colony formation in agar was assessed with the Cytoselect 96-well
cell transformation assay kit (Cell Biolabs, San Diego, CA), following
manufacturer’s instructions. Brieﬂy, 2 × 103 cells were suspended
in soft agar and plated in each well; each experiment was per-
formed by duplicate and repeated three times. Colony formation
was screened by optical microscopy twice a week for 21 days.
Wound healing assays were performed with conﬂuent cells and a
pipette tip was used to make a wound in cell monolayer. Images
were obtained at different time points during 24 hours. For cell
senescence studies, cells were ﬁxed and incubated overnight with
X-gal solution (pH 6.0) as described previously [22]. Each experi-
ment was performed by duplicate and repeated three times.
Drug Sensitivity Assay
In vitro drug sensitivity assay was performed by seeding 5 × 103
cells per well in 96-well plates (n = 6) and incubating cells in dif-
ferent cisplatin concentrations (Ebewe pharma 10 mg/20 ml).
After 24 hours, cells were washed with PBS and incubated
with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide (MTT) solution in DMEM without phenol red (0.5 mg/mL).
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After 3-hour incubation in darkness, cells were washed again
with PBS and 100 μl of dimethyl sulfoxide was added to each
well. MTT absorbance was acquired at 570 nm. Data were nor-
malized subtracting a background value, as ratio of absorbance
test (test)/absorbance control (no treatment).
Cytokines Proﬁling
Approximately 1 × 105 cells were seeded in a p6 well with com-
plete DMEM; after attachment, cells were washed with PBS and
incubated with serum-free DMEM. Supernatants were collected
24 hours later and pro-inﬂammatory cytokine pattern was ana-
lyzed using Proteome Proﬁler Human Cytokine XL Array kit
according to the manufacturer’s indications (R&D Systems, Min-
neapolis, MN). Secreted cytokine proﬁle was measured semi-
quantitatively by pixel density of duplicated spots with ImageJ.
Data were normalized subtracting background.
NF-kB Activity Assay
The activation of NF-kB was evaluated using a luciferase reporter
system [23]. 1.5 × 105 cells were seeded in a p6 well with com-
plete DMEM; after attachment, cells were transduced overnight
with a non-replicative lentiviral vector that contains the pHAGE
NF-κB-TA-LUC-UBC-GFP-W plasmid (Addgene plasmid #49343).
Then, cells were ampliﬁed for three passages and ﬁnally plated in
P96 wells. After 24 hours, cell lysis for total protein extraction was
carried out and luciferase activity was assayed with the Luciferase
Assay System (Promega Corporation, Madison, WI). Luminescent
signal was normalized against transduction efﬁciency, which was
estimated by green ﬂuorescent protein expression.
Adipogenic, Osteogenic, and Chondrogenic Cell
Differentiation
Cells were differentiated using adipogenic, osteogenic, or
chondrogenic MPCs differentiation BulletKit (Lonza, Besel-
Switzerland), following manufacturer’s instructions. For the
assessment of adipogenic differentiation, cells were ﬁxed in
4% paraformaldehyde and stained with oil red O (Sigma-
Aldrich, St. Louis, MO), osteogenic differentiation was evalu-
ated by Alizarin red staining (VWR, Radnor, PA), and chondro-
genic differentiation was determined by Alcian blue dye
(Sigma, Kawasaki, Japan) on micromass pellets previously
included in cryo-embedding media (Sakura Finetek, Alphen
aan den Rijn, Netherlands).
Western Blot Analysis
Proteins were extracted from subconﬂuent cultures by incuba-
tion on ice with lysis buffer (1% NP-40, 50 mM Tris pH 7.5,
10 mM tetrasodium pyrophosphate, 150 mM NaCl, 10 mM NaF,
1 mM PMSF, 20 mM β-glycerophosphate, 0.1 mM sodium ortho-
vanadate, and 1:100 protease inhibitor cocktail from Sigma,
St. Louis, MO). DC Protein Assay system (Bio-Rad, Hercules, CA)
was used for protein quantiﬁcation. Approximately 50 μg of pro-
teins per lane were loaded in 10% SDS-polyacrylamide gel elec-
trophoresis gels and, after electrophoretic separation, blotted
onto poly(vinylidene ﬂuoride) membranes (Bio-Rad, Hercules,
CA). Blots were incubated with primary and secondary anti-
bodies (Supporting Information Table S1) and detected using
Immobilon Western Chemiluminescent HRP Substrate (Millipore,
Burlington, MA).
Global Transcriptional Analysis and Study
Ten days after transfection, total RNA was extracted from
transduced cells. RNA (250 ng) from each biological sample
was processed and the transcriptional proﬁle was analyzed
with the use of the GeneChip Affymetrix platform and the
GeneChip Human Gene 2.0 ST Array (Santa Clara, CA). Speciﬁc
protocols, details, and expression data are available in the
Gene Expression Omnibus functional genomics data repository
(http://www.ncbi.nlm.nih.gov/geo/) under the accession num-
ber GSE79158. Data were analyzed using Bioconductor 2.12
(http://www.bioconductor.org) running on R 3.0.0. Probeset
expression measures were calculated with the Affymetrix pack-
age’s Robust Multichip Average default method. Differentially
expressed genes were assessed between samples using an
empirical Bayes t-test (limma package) and p values were
adjusted for multiple testing by the Benjamini-Hochberg
method [24]. Any probe sets that exhibited an adjusted
p value of .05 were called differentially expressed. All genes
on the Affymetrix chip were used as the background for
enrichment analyses. The p value was corrected using the Ben-
jamini and Hochberg multiple testing correction method. Dif-
ferentially expressed genes were screened for AP-1 binding
site using transcription factor binding sites predictor UCSC-
TFBS function in DAVID. Differentially expressed genes were
used to look for enrichment using Enricher tool (http://amp.
pharm.mssm.edu/Enrichr/) in Gene Ontologies (GO Molecular
Functions, 2017) and pathways (KEGG, 2016); Fisher exact test
was used to generate and compute ranking and SD from
expected rank for each term in the gene-set library and ﬁnally
calculating a z-score to assess the deviation from the expected
rank. Adjusted p < .05 was considered signiﬁcant. For GO (GO-
Biological process, 2017), only GO terms with enrichment
Z-score of <−1.40 were considered signiﬁcant. Combined score
is computed by taking the log of the p value from Fisher exact
test and multiplying that by the z-score of the derivation from
the expected rank were judged to be statistically signiﬁcant.
Alternatively, enrichment of pathways and biological GO terms
were assessed using Gene Set Enrichment Analysis (GSEA,
v2.0). Gene-sets were downloaded from MSigdb (http://
software.broadinstitute.org/gsea/msigdb) for GSEA. Gene sets
statics are indicated in each ﬁgure.
OS Meta-analysis of Clinical Samples
Microarray-based search of c-JUN, c-FOS, dipeptidyl peptidase
IV (DPPIV), platelet-derived growth factor (PDGF)-A, NFKB1,
NFKB2, and RELB mRNA expression levels in clinical samples,
its correlation to overall survival, and tumor phenotype, were
conducted using the Mixed OS—Kuijjer dataset [25], which is
available from the online R2: genome analysis and visualization
platform (http://r2.amc.nl). The Kuijjer database contains
microarray data of a cohort of 84 pretreatment diagnostic
biopsies of high-grade OSs; those data are associated with
patient’s survival and tumor phenotype. Two smaller cohorts
of ﬁbroblastic (n = 9) and osteoblastic (n = 55) OS were used
for sub-speciﬁc gene expression comparisons according to
tumor phenotype.
Animal Procedures
Immunodeﬁcient non-obese diabetic/severe combined immu-
nodeﬁcient mice of 10–12 week-old were used in the
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experiments. Cells were inoculated either subcutaneously (106
cells per mouse) or through intra-bone marrow (5 × 105 cells
per mouse). Cells were resuspended in PBS and ﬁltered
through a 70-μm nylon ﬁlter for inoculation. For intra-bone
marrow administration, anesthesia was induced by intraperito-
neal injection of a mixture of xylacine (Rompun, Bayer, Lever-
kusen, DE)–ketamine (Imalgene 1,000, Merial, Lion, FR). The
right hind limb was bent 90 to allow drilling tibial plateau
with a 25G needle before cell inoculation with a 27G needle.
Ectopic bone-like implants were realized embedding cells in
biphasic calcium phosphate crystals (Biomatlante, Vigneux-de-
Bretagne, France). In some experiments, bone morphogenic
protein 2 (BMP2) (Noricum, Madrid, Spain) was also included
as osteogenic promoting factor. For a detailed protocol of
ectopic bone-like implants follow the previously described pro-
tocol [7, 26]. Procedures were performed with the approval of
the institutions Animal Care and Use Committee, following EU
Directive for animal experiments and in a speciﬁc pathogen-
free environment.
Histological Processing
Samples were washed twice with cold PBS and ﬁxed 24 hours
in 10% neutral-buffered formalin. Tumors were decalciﬁed
with 4% hydrogen chloride/4% formic acid in water during
3 days or alternatively with 17% EDTA (Osteosoft, Millipore,
Burlington, MA) during 7 days. Then samples were processed
for sectioning, parafﬁn embedded, and sectioned (8 μm) for
histological studies. Hematoxylin/eosin, Masson’s trichrome,
and Alcian blue stainings were performed.
Micro-computed Tomography
Formalin-ﬁxed samples were imaged in an eXplore Vista μCT
system (GE Healthcare, Chicago, IL), with an X-ray tube voltage
of 50 kV and a current of 200 μA. The scanning angular rota-
tion was 180, the angular increment was 0.40, and the voxel
resolution was 50 μm. Data sets were reconstructed and seg-
mented into binary images (8-bit BMP images) for the subse-
quent image processing and 3D surface reconstructions using
MicroView ABA 2.2 software (GE Healthcare).
Immunostaining
Immunohistochemistry (IHC) studies were performed by stan-
dard methods; heat antigen retrieval was performed when
required in IHC studies (see primary unconjugated antibodies
used in Supporting Information Table S1). Secondary ﬂuores-
cent antibodies were from Invitrogen and secondary biotiny-
lated antibodies were from Jackson (Bar Harbor, ME). Texas
Red-X phalloidin (Invitrogen, Carlsbad, CA) was used for actin
staining.
Statistics
Experiments were performed at least by triplicate. Data were
expressed as means  SD or SEM. Student t test and analysis
of variance (ANOVA) analysis were performed using Graph Pad
Prism 6 software (La Jolla, CA). One-way ANOVA was used to
compare statistical difference in more than two groups, with
Bonferroni post hoc test. For multiple comparisons, a conﬁ-
dence interval of 95% was adopted and only p values inferior
to .05 were considered statistically signiﬁcant. p value is indi-
cated in each panel and ﬁgure (*, p ≤ 0.05; **, p ≤ 0.01; ***,
p ≤ 0.001; ****, p ≤ 0.0001).
RESULTS
AP-1 Overexpression Induces Transformation
of Immortalized hMSC
First, we use lentiviral gene transfer to overexpress c-JUN or
c-JUN/c-FOS in wild-type hMSC. We observed no changes in the
proliferation rate, cell cycle distribution, or senescence levels
after the overexpression of these factors (Supporting Informa-
tion Fig. S1). In addition, no tumor growth was detected when
these cells were inoculated into immunodeﬁcient mice. Since it
was reported that several oncogenic events are needed to fully
transform hMSCs [8, 9], we next use the same vectors in hMSC
previously immortalized through the sequential introduction of
several oncogenic hits (i.e., ectopic expression of hTERT and
inactivation of p53 and Rb by the expression of the E6 and E7
antigens of HPV-16; MSC-3H cells). The efﬁcient generation of
cells overexpressing c-JUN (3H-JUN) or c-JUN and c-FOS (3H-
JUN/FOS) was conﬁrmed both by Western blotting (Fig. 1A) and
ﬂow cytometry analysis of the ﬂuorescence produced by the
reporter genes included in c-JUN and c-FOS lentiviral vectors
(Fig. 1B). Interestingly, ﬂow cytometry study also reveals rele-
vant changes in cellular morphology, being cell size and com-
plexity reduced after c-JUN and specially c-JUN and c-FOS
expression (Fig. 1C); those changes in cell morphology were also
conﬁrmed by light microscopy (Fig. 1D). in vitro proliferation
assays showed that 3H-JUN cells proliferate faster than control
and 3H-JUN/FOS cells (Fig. 1E). In addition, both 3H-JUN and
3H-JUN/FOS showed a reduction in the G1 phase and a concomi-
tant increase in S and G2/M of the cell cycle as compared to
control cells (Fig. 1F). Moreover, immortalized hMSC overex-
pressing c-FOS and/or c-JUN showed evident signs of cell trans-
formation in vitro. Thus, 3H-JUN/FOS lost contact inhibition and
started to grow forming multi-layered clumps (Fig. 1G). In addi-
tion, both 3H-JUN and 3H-JUN/FOS cells were able to grow
forming colonies in soft agar (Fig. 1H). Furthermore, wound
healing assays showed that the expression of c-JUN or c-JUN/c-
FOS did not affect the migration ability of immortalized hMSCs
(Fig. 1I), and ﬁnally, 3H-JUN and 3H-JUN/FOS cells displayed a
highly increased sensitivity to chemotherapeutic drugs like
cisplatin (Fig. 1L). In summary, these data (Fig. 1) support
that AP-1 overexpression contributed to the transformation
of immortalized hMSCs in vitro inducing consistent changes
in their growth properties and sensitizing them to cytotoxic
drugs.
c-JUN and c-JUN/c-FOS Overexpression Unbalance
Similar Cellular Pathways
Next, we performed gene expression analysis to identify molec-
ular pathways altered by the overexpression of c-JUN and
c-JUN/c-FOS in immortalized hMSCs (Fig. 2). We found that
587 and 779 genes were differentially expressed in 3H-JUN and
3H-JUN/FOS, respectively, relative to control 3H cells (Fig. 2A).
In total, 53.3% of these altered genes were commonly altered
in both cell lines, while 12.6% and 34.1% of the genes were spe-
ciﬁcally dysregulated in 3H-JUN and 3H-JUN/FOS cells. A predic-
tive transcription factor binding study identiﬁed those altered
genes presenting AP-1 promoter responsive elements in their
sequence (Supporting Information Table S2). Among this subset
of genes, 86 were exclusively overexpressed in 3H-JUN/FOS
cells, 25 genes were exclusively overexpressed in 3H-JUN cells,
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Figure 1. Expression of c-JUN or c-JUN/c-FOS induces cell transformation in vitro. (A): c-JUN and c-FOS protein levels in control 3H (3H-
), 3H-JUN (3H-J), and 3H-JUN/FOS (3H-JF) cells analyzed by Western blot. α-Tubulin levels were used as loading control. Uninformative
lanes were cut out. (B): Flow cytometry evaluation of EGFP (left panel) and TdTomato (right panel) reporter gene expression levels in con-
trol 3H (black line), 3H-JUN (green line), and 3H-JUN/FOS (orange line) cells. (C): Size (FSC) and complexity (SSC) changes detected in con-
tour plots comparing 3H- cells (black contour) with 3H-J (green; left panel) or 3H-JF (orange; right panel). (D): Representative light
microscopy images of 3H-, 3H-J, and 3H-JF cell lines showing changes in cellular morphology. (E): in vitro proliferation of 3H-, 3H-J,
and 3H-JF cell lines. (F): Flow cytometry quantiﬁcation of the percentage of cells in each phase of the cell cycle; cell lines are indicated on
the x-axis. (G, H): Representative images of in vitro transformation assays showing the ability of 3H-JF cells to grow forming multilayered
clumps (G), and the ability of 3H-J and 3H-JF cells to form colonies in soft-agar (H). (I): Representative images of the wound healing assay
indicating no differences in cell mobility between 3H-, 3H-J, and 3H-JF cell lines. (J): Cell viability (MTT assay) measured after treating
3H-, 3H-JUN, and 3H-JUN/FOS cells for 24 hours with the indicated concentrations of cisplatin. Abbreviations: EGFP, enhanced green
ﬂuorescent protein; FSC, forward scatter; SSC, side scatter.
Table 1. In vivo tumorogenesis
T.I. Incidence Latency VIM KI-67 OSN OSC S-100 COLL2 Diagnosis
hMSC-cJUN s.c. 0/6 − Not tumorigenic
hMSC-cFOS s.c. 0/6 − Not tumorigenic
3H- s.c. 0/15 − Not tumorigenic
Tibia 0/8 −
3H-JUN s.c. 13/13 60–150 + 50% + + − − Fibroblastic OS
Tibia 2/4 150–170 + 5% + + − −/+ Fibroblastic/low grade OS
3H-JUN/FOS s.c. 14/14 20–60 + 80% + −/+ − −/+ Pleomorphic/osteoblastic OS
Tibia 5/5 32–40 + 20% + + −/+ − Pleomorphic/osteoblastic OS
Incidence indicates the number of animals developing tumors over the total of the inoculated animals. Latency was calculated as the time
(expressed in days) needed to reach a tumor volume of 1 cm3.
Abbreviations: COLL2, collagen type II; hMSC, human mesenchymal stem cell; OS, osteosarcoma; OSC, osteocalcin; OSN, osteonectin; S100, S100
calcium binding protein; T.I.: tumor inoculation procedures divided in subcutaneous ectopic (s.c.) and orthotoic (Tibia) inoculation; VIM, human
vimentin.
©2018 The Authors Stem Cells published by Wiley Periodicals, Inc. on behalf of AlphaMed Presswww.StemCells.com
Gambera, Abarrategi, Rodríguez-Milla et al. 1491
and 88 genes were commonly overexpressed (Fig. 2B). Similarly,
104 and 35 genes were speciﬁcally downregulated in 3H-JUN/
FOS and 3H-JUN, respectively, while 165 genes were commonly
downregulated (Fig. 2B). KEGG pathways and GO Molecular
Functions terms analysis of the commonly dysregulated genes
identiﬁed the enrichment of differentially expressed genes in
pathways related to cancer, including extracellular matrix recep-
tor interactions, Wnt and PI3K/Akt signaling, cell adhesion
molecules, growth factors, cytokines, and chemokines
(Supporting Information Table S2). Among the private differen-
tially expressed genes in 3H-JUN/FOS, most of the altered genes
were tyrosine and threonine kinases, with enrichment in MAPK
signaling, osteoclast differentiation, and focal adhesion, as other
additional alteration in cancer pathways and PI3K/Akt signaling
(Supporting Information Table S2). The total amount of differen-
tially expressed genes, even not presenting AP-1 transcription
Figure 2. Gene expression analysis of 3H-JUN and 3H-JUN/FOS cells. (A, B): Venn diagrams representing the number, percentage, and
overlay of genes differentially expressed in 3H-JUN (3H-J) and 3H-JUN/FOS (3H-JF) relative to control 3H- cells (A), or the same analysis
restricted to those genes presenting a transcription factor binding site for AP1 and subdivided into upregulated (left panel) and downre-
gulated (right panel) genes (B). (C): Gene Ontology terms enriched signatures in biological process of proliferation, differentiation, and
apoptosis of chondrocytes, grow plate cartilage chondrocytes, osteoblasts, mesenchymal cells, and mesenchymal stem cells. Positive regu-
lation (R+) and negative regulation (R–) signatures are presented; R indicates regulation signature not included into stimulating or inhibi-
tory processes. Also changes in collagen and matrix organization, assembly and disassembly like bone and skeletal system development
were enriched. (D, E): Cell cycle-related Gene Set Enrichment Analysis enriched plots in 3H-JUN (D) and 3H-JUN/FOS cells (E). Abbrevia-
tions: AP, apoptosis; CH, chondrocytes; GPCC, grow plate cartilage chondrocytes; MC, mesenchymal cells; MSC, mesenchymal stem cells;
OB, osteoblasts.
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factor binding site, matched the enrichment of different GO
terms implicated in proliferation, differentiation, migration, and
apoptosis of chondrocyte, osteoblast, and MSC (Fig. 2C). Fur-
thermore, we also found enriched signatures related to bone
and skeletal development as extracellular matrix organization
(Fig. 2C) (The complete GO terms enrichment analysis is avail-
able separately in Supporting Information Tables S3, S4). Nota-
bly, the alterations of cell cycle-related pathways were further
conﬁrmed by GSEA (Fig. 2D, 2E).
c-JUN or c-JUN/c-FOS Overexpression Does Not Affect
the in vitro Osteochondrogenic Differentiation
Potential
To deﬁne whether the expression of AP-1 transcription factors
could affect the differentiation potential of immortalized
hMSCs, we tested the ability of 3H-JUN and 3H-JUN/FOS cells to
undergo adipogenic, osteogenic, and chondrogenic differentia-
tion in vitro (Fig. 3). 3H-JUN cells displayed an impaired pattern
of adipogenic differentiation similar to that previously observed
for 3H- cells [15], whereas 3H-JUN/FOS cells were completely
unable to form lipid droplets ﬁlled adipocytic-like cells when
they were cultured in adipogenic medium. In contrast, all the
cell lines efﬁciently generated alizarin red-positive calcium
deposits under osteogenic stimulation and alcian blue-positive
matrix deposits after micromass culture in chondrogenic assays.
In summary, our data indicate that c-JUN and c-JUN/c-FOS over-
expression in immortalized hMSCs does not alter their osteo-
chondrogenic potential in vitro.
Ectopic in vivo Implantation of 3H-JUN and 3H-JUN/
FOS Cells Generates Phenotypically Different OSs
To assay the in vivo tumorigenic potential, we ﬁrst inoculated
immunodeﬁcient mice subcutaneously with control cells or cells
overexpressing AP-1 transcription factors. Opposite to control
3H- cells, which were unable to initiate tumor growth, both
3H-JUN and 3H-JUN/FOS cells generated tumors with 100% of
incidence, showing 3H-JUN/FOS cells a shorter latency (Table
1). Histological analysis of these tumors conﬁrmed the develop-
ment of two phenotypically different types of OSs. Hematoxy-
lin/eosin and Masson’s trichrome staining revealed that 3H-JUN
(Fig. 4A) and 3H-JUN/FOS (Fig. 4B) tumors presented ﬁbroblas-
tic and pleomorphic osteoblastic phenotypes, respectively. In
the ﬁrst case, the characteristic osteoid matrix was organized in
ﬁbrillary structures, while in the second, osteoid matrix were
surrounding cells presenting different morphologies, including
areas of a myxoid chondrogenic phenotype (Fig. 4). Immunohis-
tochemistry analysis showed that both the types of OSs were
positive of osteogenic (osteocalcin and osteonectin) and mes-
enchymal (vimentin) markers, whereas chondrogenic markers
(COLL2 and S100) were negative in 3H-JUN cells and only
Figure 3. c-JUN or c-JUN/c-FOS overexpression in immortalized human mesenchymal stem cell does not affect their in vitro osteo-
chondrogenic potential. Representative images of oil red O (up), alizarin red (middle), and alcian blue (bottom) staining after in vitro
adipogenic, osteogenic, and chondrogenic differentiation of 3H (3H-), 3H-JUN (3H-J), and 3H-JUN/FOS (3H-JF) cells (n = 6). Scale
bars = 50 and 100 μm
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partially positive (dispersed areas of COLL2 staining) in 3H-JUN/
FOS cells (Fig. 4 and Table 1).
To further characterize the ability of cells overexpressing
c-JUN or c-JUN/c-FOS to initiate OS formation in ectopic condi-
tions which better mirror bone environmental conditions, we
use a previously described ceramic model in which cells were
embedded in hydroxyapatite (HA)/tricalcium phosphate, as cal-
ciﬁed substrates that resemble bone calciﬁed extracellular
matrix, in the presence or absence of an osteoinductive factor
abundant in the bone milieu such as BMP2 [7, 26]. Subcutane-
ous implantation of these models resulted in the formation of
OS with similar phenotypes than those observed after direct
Figure 4. Ectopic inoculation of 3H-JUN and 3H-JUN/FOS cells generates osteosarcomas with ﬁbroblastic and pleomorphic phenotypes.
Representative images of the histological analysis of tumors generated after the subcutaneous inoculation of 3H-JUN (A) or 3H-JUN/FOS
cells (B). (A) Hematoxylin/eosin and Masson’s trichrome staining evidence that 3H-JUN cells form osteosarcoma (OS) characterized for
osteoid deposition promoted by ﬁbroblastic cells positive for osteogenic differentiation (osteocalcin [OSC] and osteonectin [OSN]) and
mesenchymal (human vimentin) markers. In addition, tumor cells are negative for chondrogenic markers (COLL2 and S100). (B): 3H-JUN/
FOS cells generate pleomorphic OS characterized by the expression of OSN and to a lesser extension of OSC. These tumors also display
dispersed areas showing a myxoid chondrogenic phenotype and positivity for collagen type II marker. Scale bars = 50, 100, and 200 μm.
Abbreviations: COLL2, collagen type II; HE, hematoxylin/eosin; MT, Masson’s trichrome; OSC, osteocalcin; OSN, osteonectin; S100, S100
calcium binding protein; VIM, human vimentin.
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inoculation of cells. Thus, 3H-JUN cells generated osteoid-
forming tumors organized in longitudinal ﬁbers with ﬁbroblas-
tic phenotype (Supporting Information Fig. S2) and, on the
other hand, 3H-JUN/FOS tumors are formed by osteoid-
forming pleomorphic cells and include areas of myxoid pheno-
type in response to HA and BMP2 stimulation (Supporting
Information Fig. S2).
In summary, our results show that the overexpression of
c-JUN or C-JUN and c-FOS fully transforms immortalized hMSCs
giving rise to OS presenting different phenotypes in vivo.
Orthotopic in vivo Inoculation of 3H-JUN and 3H-JUN/
FOS Cells Generate Phenotypically Different OSs
Bone environment has been proved to play essential roles in
OS development [7, 27]. Therefore, we studied whether the
inoculation of the cells in an orthotopic model could modulate
the tumor phenotype observed after ectopic inoculation. Both
3H-JUN and 3H-JUN/FOS cells generated tumors when inocu-
lated in the proximal tibia of immunodeﬁcient mice. 3H-JUN
cells presented a higher latency and a lower incidence
(Supporting Information Table S5) and developed tumors that
moderately affected bone cortex as conﬁrmed by micro-
computed tomography analysis (Fig. 5). In contrast, 3H-JUN/
FOS cells showed a more aggressive phenotype; the mice that
rapidly developed osteolytic lesions are able to compromise
the limb structure and functionality (Fig. 5). Histological study
indicated that both the cell lines formed OS. Tumors formed
by 3H-JUN cells were composed of spindle-shaped cells which
produced a small amount of osteoid matrix. These tumoral
cells were organized in a ﬁbroblastic geometry and displayed a
herringbone pattern (Fig. 6A). On the other hand, 3H-JUN/FOS
cells developed tumors presenting large osteogenic areas and
aberrant trabeculae formation promoted by pleomorphic cells
(Fig. 6B). Immunohistochemistry analysis also conﬁrmed OS
diagnosis (Fig. 6; Table 1). In both the cases, tumors presented
immunoreactivity for typical osteogenic (osteocalcin, osteonec-
tin) and mesenchymal (vimentin) markers, while staining for
chondrogenic markers (S100 and collagen II) was focal and lim-
ited to small areas.
Altogether, these results show that the overexpression of
c-JUN or c-JUN and c-FOS is relevant to transforming events
that are able to initiate osteosarcomagenesis from hMSCs
independent of microenvironment factors. c-JUN overexpres-
sion is linked to the appearance of a ﬁbroblastic phenotype,
whereas the double overexpression of c-JUN and c-FOS shifts
the phenotype to that observed in pleomorphic
osteoblastic OS.
c-JUN and c-JUN/c-FOS Overexpression Induces in vitro
Changes in NF-kB Activity and Cytokines Secretion
Our gene expression study uncovered signiﬁcant changes in
the mRNA levels of different cell-to-cell signaling molecules
after cell transformation (GO molecular functions, Supporting
Information Table S2). To further investigate the changes
induced by c-JUN and C-JUN/c-FOS expression that could
affect the local tumor microenvironment, we study the cyto-
kine secretion proﬁle of 3H-JUN and 3H-JUN/FOS cells
in vitro (Supporting Information Fig. S3). The expression of c-
JUN and c-JUN/c-FOS modulated the secretion of a panel of
cytokines (Supporting Information Fig. S3A), which changes
were in accordance with those observed in mRNA levels
(Supporting Information Fig. S3B). Interestingly, 3H-JUN/FOS
cells showed the more evident changes and most of the
cytokines modulated in these cells were downregulated.
Among the cytokines upregulated by c-JUN or C-JUN/c-FOS,
PDGF-A transcription, and secretion was upregulated in both
3H-JUN and 3H-JUN/FOS cells, while DPPIV (or CD26) was
speciﬁcally upregulated at both mRNA and protein levels in
3H-JUN/FOS cells (Fig. 7A, 7B). Our previous in vivo experi-
ments show that 3H-JUN/FOS cells induced a more aggres-
sive disease and osteoblastic tumor phenotype, while 3H-JUN
cells induced a less aggressive ﬁbroblastic OS. To test the
relation between those speciﬁc cytokines and tumor pheno-
type, we studied their gene expression levels in a microarray
dataset of OS clinical samples (pretreatment biopsies). As in
3H-JUN/FOS cells, high levels of DPPIV correlate to a worse
prognosis and show a tendency to associate with an osteo-
blastic phenotype in human clinical samples (Fig. 7C). In
addition, PDGF-A expression levels also correlated with prog-
nosis, although they were not signiﬁcantly different between
patients presenting ﬁbroblastic and osteoblastic phenotypes
(Fig. 7D).
NF-kB is a transcription factor complex frequently dysregu-
lated in several cancer types; NF-kB modulates the transcrip-
tion of different genes involved in stress response and
inﬂammation, including cytokines regulation. Therefore, we
decided to test the activation status of this transcription factor
following c-JUN and c-JUN/c-FOS overexpression in immortal-
ized cells. To quantify NF-kB activity, we transduced trans-
formed hMSCs with a lentiviral vector expressing ﬁreﬂy
luciferase reporter gene downstream of NF-kB responsive tran-
scriptional elements. Quantiﬁcation of luciferase activity in
efﬁciently transfected cells showed that 3H-JUN cells pre-
sented higher NF-kB transcriptional activity than 3H- and 3H-
JUN/FOS cells (Fig. 7E). Therefore, a higher NF-kB activation
status in transformed cells in vitro correlated with a less
Figure 5. Micro-computed tomography imaging of osteosarco-
mas formed upon intrabone inoculation of 3H-JUN and 3H-JUN/
FOS cells. Representative radiographic images (sagittal plane)
showing mice tibiae inoculated with vehicle (phosphate-buffered
saline; left panel), 3H-JUN (3H-J; middle panel), or 3H-JUN/FOS
(3H-JF; right panel) cells. Mice inoculated with 3H-JUN develop
tumors presenting moth-eaten geographic lesions affecting bone
cortex, while those inoculated with 3H-JUN/FOS cells develop
more aggressive tumors presenting a highly osteolytic phenotype
which is also characterized by a prominent speculated periosteal
reaction with sunburst appearance. Abbreviation: PBS, phosphate-
buffered saline.
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aggressive disease and a ﬁbroblastic phenotype of tumors.
We further tested this association comparing the transcrip-
tion levels of c-JUN, c-FOS, and different members of NF-kB
transcription factor complexes in clinical samples. As in our
model, the differential composition of AP-1 transcription fac-
tor determinate tumor phenotype, so in clinical samples,
c-JUN expression levels do not associate with tumor pheno-
type, while c-FOS levels are upregulated in osteoblastic OS
tumors (Fig. 7F). Furthermore, similar to our model, in human
samples transcription levels of the NF-kB components RELB,
NFKB1, and NFKB2 correlate to a better overall survival and a
ﬁbroblastic OS phenotype (Fig. 7G–7I). In sum, our data point
out the relevance of different AP-1 members in regulating
NF-kB functionality, where low levels of NF-kB activity do
associate to reduced patients survival and a speciﬁc tumor
phenotype.
Figure 6. Orthotopic inoculation of 3H-JUN and 3H-JUN/FOS cells generates ﬁbroblastic and pleomorphic osteoblastic osteosarcoma,
respectively. Representative images of the histological analysis of tumors generated after the orthotopic inoculation of 3H-JUN (A) and
3H-JUN/FOS (B) cells. Hematoxylin/eosin and Masson’s trichrome staining evidence the formation of osteosarcoma displaying osteoid
matrix deposition generated by cells with ﬁbroblastic morphology positive for osteogenic (osteocalcin and osteonectin) and mesenchymal
(human vimentin) markers and partially positive (COLL2) or negative (S100) for chondrogenic markers. Scale bars = 50, 100, and 200 μm.
Abbreviations: COLL2, collagen type II; HE, hematoxylin/eosin; MT, Masson’s trichrome; OSN, osteonectin; OSC, osteocalcin; S100, S100
calcium binding protein; VIM, human vimentin.
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DISCUSSION
Different studies support the idea that increased expression of
AP-1 is associated with human tumorigenesis [28]. The overex-
pression of c-JUN or the combination of c-JUN/c-FOS in
healthy hMSC is not sufﬁcient to induce cell transformation;
therefore, we studied the effect of their overexpression in
immortalized hMSCs. Conﬁrming the oncogenic potential of
the AP-1 complex, the expression of its components was sufﬁ-
cient to induce proliferation, alter cell cycle, induce morpho-
logical changes, and generate OS in vivo from immortalized
hMSCs. Various studies have demonstrated that the differen-
tial dimerization between JUN and FOS members alters the
promoter-binding activity, the transcriptional capacity, the
Figure 7. c-JUN or c-JUN/c-FOS overexpression in immortalized human mesenchymal stem cell induces changes in cytokines release and
nuclear factor-kB (NF-kB) pathway. (A) Dipeptidyl peptidase IV (DPPIV) and platelet-derived growth factor (PDGF)-A genes expression levels
of transduced cells according to the values obtained in the microarray analysis presented in Figure 2. Data are presented as fold changes to
control 3H- cells. (B): Levels of DPPIV and PDGF-A secreted to the medium in 3H-JUN and 3H-JUN/FOS cultures. Data are presented as fold
changes to control 3H- cells. Error bars represent SEM. Statistic tests: two-way analysis of variance (ANOVA) and Bonferroni post hoc test,
CI: 95%, alpha: 0.05. p < .0001 (****). (C) Kaplan–Meier survival analysis (left) and mRNA expression level (right) of DPPIV gene in human
clinical samples. (D): Kaplan–Meier survival analysis (left) and mRNA expression level (right) of PDGF-A gene in human clinical samples. (E):
NF-kB promoter activity in transduced cells. Data are normalized to lentiviral transduction efﬁciency. Statistic tests: two-way ANOVA and
Bonferroni post hoc test, CI: 95%, alpha: 0.05. p < .0001 (****). (F): mRNA expression level of c-JUN and c-FOS genes in human clinical sam-
ples. (G, I): Kaplan -Meier survival analysis (left) and mRNA expression level (right) of NFKB2 (G), NFKB1 (H), and RELB (I) genes in human
clinical sample dataset. mRNA expression levels are graphed as box plot where error bars represents maximum and minimum values. Statis-
tic tests for Kaplan–Meier survival analysis and mRNA expression levels comparison are presented in Supporting Information Table S5.
Abbreviations: DPPIV, dipeptidyl peptidase IV; OS, osteosarcoma; PDGF-A, platelet-derived growth factor-A.
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protein stability, and the transcriptional repertoire of the AP-1
complex [16, 29–31]. However, the differential role of homodi-
meric versus heterodimeric AP-1 complex in hMSCs biology is
mostly unknown. To gain new insight, we studied the gene
expression proﬁle and the differential gene expression of
immortalized hMSCs overexpressing c-JUN or c-JUN/c-FOS.
According to the ability of the joined expression of c-JUN and
c-FOS to dysregulate a higher number of genes, 3H-JUN/FOS
cells showed more differentially expressed genes and higher
enriched GO terms. More relevant alterations detected in gene
expression studies were related to changes in cell cycle, prolif-
eration, and differentiation processes, as genes with growth
factor, cytokine, and chemokine activity. Indeed, transgenes
expression in immortalized cells induced an increased secre-
tion of PDGF-A. It was shown that PDGF-A overexpression gen-
erates an autocrine loop promoting OS cells growth and its
expression was reported as prognostic factor and therapeutic
target (Gleevec) in OSs [32] and soft tissue sarcomas [33]. Fur-
thermore, PDGF-A exerts a paracrine effect as chemotactic
and differentiating factor for mesenchymal cells [34] including
MSCs. In this regard, different studies have investigated the
role of healthy MSCs in tumor microenvironment, with oppo-
site results of pro- and anti-tumorigenic effect on tumor
growth and metastatic spread [35, 36]. Given their biological
properties and their inﬂuence on tumor growth, MSCs repre-
sent cells with unique characteristic in both cell transformation
and tumor microenvironment regulation [37].
Another interesting ﬁnding in our data is the augmented
secretion of DPPIV of 3H-JUN/FOS cells, where its overexpres-
sion correlated with tumor aggressiveness and osteoblastic
tumor phenotype in our samples. This ﬁnding was further con-
ﬁrmed in clinical data, where higher gene expression levels
correlate to osteoblastic OS and a worse overall survival in
patients. This signaling molecule was implicated in the immu-
nological regulation and processing of different growth factors,
cytokines, and chemokines. DPPIV/CD26 plays a speciﬁc role in
osteoclast development [38], is associated with osteolytic
lesions [39], and further represent a prognostic marker in OS
[40]. Interestingly, this gene contains in its promoter putative
binding sequences for both AP1 and NF-kB transcription fac-
tors [41].
NF-kB transcription factor has a well-known implication in
oncogenesis; different reports showed that NF-kB can function
both as an oncogene or tumor suppressor gene depending on
the cell context and cancer type [42]. NF-KB activation was
associated with osteosarcomagenesis [43, 44], where the inhi-
bition of this factor in cell lines was sufﬁcient to revert malig-
nant development [45]. In our study, we found that the
homodimeric or heterodimeric composition of AP1 can differ-
entially modulate NF-kB activity, correlating also to speciﬁc
tumor phenotype and tumor aggressiveness. Thus, in accor-
dance with the ability of 3H-JUN cells to induce ﬁbroblastic OS
with a less aggressive disease development and high levels of
NF-kB activity, a higher expression of different members of NF-
kB complex correlates to an increased overall survival and/or
to ﬁbroblastic OS phenotype in clinical samples. Similarly, the
fact that 3H-JUN/FOS cells induce osteoblastic OS showing a
more aggressive disease and lower levels of NF-kB activity, par-
allels the ﬁnding in clinical samples where a lower expression
of NF-kB complex members correlates to OS with an osteoblas-
tic phenotype and a more aggressive behavior.
Previous studies of our laboratory indicated that c-FOS
overexpression in immortalized hMSC generated chondrogenic
tumors. The data presented here complete this frame suggest-
ing that the overexpression of AP-1 factor in hMSCs is a key
factor in the development of different bone tumors and that
abundance of the different homo/heterodimers of this tran-
scription factor could modulate the ﬁnal phenotype. c-JUN
overexpression would be speciﬁcally associated with the devel-
opment of OS and that the concurrent enhanced expression of
c-FOS could modulate the aggressiveness and the phenotype
of the OS. Importantly, OS tumor phenotype was recognized
as prognostic factor. In this line, osteoblastic OS patients dis-
played up to 20% lower 5-year event-free survival rates than
patients with the ﬁbroblastic phenotype [46, 47]. Resembling
this clinical observation, our model of c-JUN-expressing ﬁbro-
blastic OS showed a less aggressive behavior than the c-JUN/
c-FOS expressing pleomorphic conventional OS. Thus, signs of
malignancy, such as the presence of cortical breakthrough, soft
tissue mass generation, permeative development, and perios-
teal reaction were much more evident in tumors developed by
c-JUN/c-FOS overexpressing cells. On the other hand, the geo-
graphic and moth-eaten pattern of bone destruction observed
in tumors derived from 3H-JUN cells represented less malig-
nant lesions. Higher tumor incidence and lower latency were
observed with 3H-JUN/FOS cells compared with 3H-JUN cells.
Altogether, these data support the idea that some genetic hits
could be effectively responsible for inducing MSCs transforma-
tion and at the same time, a speciﬁc tumor phenotype. Fur-
thermore, the effect of this alteration is not restricted only to
the inner cell differentiation program but is extended, with a
pattern of signaling molecules, to the tumor microenviron-
ment. Speciﬁcally, our two models of OS based on the overex-
pression of c-JUN or c-JUN and c-FOS reﬂect different
phenotypes and behaviors of the human disease.
In the clinical setting, AP-1 may represent a promising drug
target due to its implication in tumor development and pro-
gression. Different studies have provided evidence that drugs
like glucocorticoids, dexamethasone, heparin, and aspirin or
other more natural compounds, like green tea polyphenols, oil
ﬁsh, curcumin, and cannabinol could modulate AP-1 functions
[48, 49]. These and other AP-1 inhibitors could effectively
interfere with oncogene-induced transformation and tumor
cell growth, although their effectiveness in OS treatment still
requires a thorough investigation. Our results highlight the rel-
evant role that AP-1 factors may play in OS development, and
suggest their possible use as biomarkers for patient stratiﬁca-
tion and future therapeutic design.
CONCLUSION
Our ﬁndings uncover the implication of AP-1 complex in osteo-
sarcomagenesis. Our study shows that some genetic hits could
be responsible for inducing MSCs transformation and simulta-
neously, a speciﬁc tumor phenotype. Here, we found that the
overexpression of different AP-1 complex members can give
rise to OS presenting speciﬁc phenotypes. Speciﬁcally, overex-
pression of c-JUN induces ﬁbroblastic OS and c-JUN/c-FOS
osteoblastic OS, where NF-kB transcription factor would have
a role in determining these different tumor entities.
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